公开(公告)号：US20250009951A1

公开(公告)日：2025-01-09

申请号：US18713370

申请日：2022-11-29

Applicant: CYTOSORBENTS CORPORATION

Inventor： Phillip P. CHAN ,  Karl-Gustav RUGGEBERG ,  Ritu TRIPATHI ,  Ophir ORTIZ ,  Richard R. MCKAY

IPC: A61M1/36 ,  B01J20/26 ,  B01J20/28

Abstract: Methods of treating cancer in a subject by administering a therapeutically effective amount of a porous biocompatible sorbent are disclosed. The porous biocompatible sorbents comprise a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5.0 cc/g dry polymer.

公开(公告)号：US20220032271A1

公开(公告)日：2022-02-03

申请号：US17298968

申请日：2019-12-02

Applicant: CytoSorbents Corporation

Inventor： Tamaz GULIASHVILI ,  Maryann GRUDA ,  Thomas GOLOBISH ,  David JAMES ,  Karl-Gustav RUGGEBERG ,  Pamela O'SULLIVAN ,  Sarah PATTERSON

IPC: B01J20/32 ,  C07K16/06 ,  C07K1/22 ,  B01J20/28 ,  B01D15/38

Abstract: The invention concerns polymeric media based on modified natural polysaccharides for removing one or both of Anti-A Antibodies and Anti-B Antibodies from human blood or plasma, the media comprising one or both of (i) a polymeric solid support with a blood group A Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions, and (ii) a polymeric solid support with a blood group B Antigen ligand attached to the solid support at a ligand loading between 1-5 mg/mL of solid support, and wherein the media is stable under physiological pH conditions.